Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet?

被引:48
作者
Geyer, Felipe Correa [1 ]
Reis-Filho, Jorge Sergio [1 ]
机构
[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Mol Pathol Lab, London SW3 6JB, England
关键词
gene expression; microarray; gene signature; prognostic; predictive; COMPARATIVE GENOMIC HYBRIDIZATION; INVASIVE DUCTAL CARCINOMA; 21-GENE RECURRENCE SCORE; IN-SITU HYBRIDIZATION; BASAL-LIKE SUBTYPE; ADJUVANT CHEMOTHERAPY; PROGNOSTIC SIGNATURE; MOLECULAR SUBTYPES; PREOPERATIVE CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1177/1066896908328577
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Breast cancer is a heterogeneous disease, encompassing several histological types and clinical behaviors. Current histopathological classification systems are based on descriptive entities with prognostic significance. Few prognostic and predictive markers beyond those offered by histopathological analysis are available. High-throughput molecular technologies are reshaping our understanding of breast cancer, of which microarray-based gene expression has received most attention. This method has been used to derive a Molecular taxonomy for breast cancer, which has provided interesting insights into the biology of the disease. Class prediction Studies have generated a multitude of prognostic/predictive signatures, which herald the promise for an improvement in treatment decision making. However, most of the signatures developed to date seem to have discriminatory power almost restricted to estrogen receptor-positive disease. This review addresses the contribution of gene expression profiling to our understanding of breast cancer and its clinical management.
引用
收藏
页码:285 / 302
页数:18
相关论文
共 161 条
[1]   Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: Further evidence to support the concept of low nuclear grade breast neoplasia family [J].
Abdel-Fatah, Tarek M. A. ;
Powe, Desmond G. ;
Hodi, Zsolt ;
Reis-Filho, Jorge S. ;
Lee, Andrew H. S. ;
Ellis, Ian O. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (04) :513-523
[2]   High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma [J].
Abdel-Fatah, Tarek M. A. ;
Powe, Desmond G. ;
Hodi, Zsolt ;
Lee, Andrew H. S. ;
Reis-Filho, Jorge S. ;
Ellis, Ian O. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (03) :417-426
[3]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[4]   High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates [J].
Alexe, Gabricla ;
Dalgin, Gul S. ;
Scanfeld, Daniel ;
Tamayo, Pablo ;
Mesirov, Jill P. ;
DeLisi, Charles ;
Harris, Lyndsay ;
Barnard, Nicola ;
Martel, Maritza ;
Levine, Arnold J. ;
Ganesan, Shridar ;
Bhanot, Gyan .
CANCER RESEARCH, 2007, 67 (22) :10669-10676
[5]   Molecular characterization of the tumor microenvironment in breast cancer [J].
Allinen, M ;
Beroukhim, R ;
Cai, L ;
Brennan, C ;
Lahti-Domenici, J ;
Huang, HY ;
Porter, D ;
Hu, M ;
Chin, L ;
Richardson, A ;
Schnitt, S ;
Sellers, WR ;
Polyak, K .
CANCER CELL, 2004, 6 (01) :17-32
[6]   DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design [J].
Andre, Fabrice ;
Mazouni, Chafika ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2006, 1766 (02) :197-204
[7]   Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy [J].
Andre, Fabrice ;
Pusztai, Lajos .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (11) :621-632
[8]   Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) [J].
不详 .
LANCET ONCOLOGY, 2007, 8 (12) :1079-1087
[9]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[10]   Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J].
Banerjee, S. ;
Reis-Filho, J. S. ;
Ashley, S. ;
Steele, D. ;
Ashworth, A. ;
Lakhani, S. R. ;
Smith, I. E. .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) :729-735